KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Net Income (2016 - 2026)

Gsk has reported Net Income over the past 18 years, most recently at $2.9 billion for Q1 2026.

  • For Q1 2026, Net Income rose 8.87% year-over-year to $2.9 billion; the TTM value through Mar 2026 reached $10.0 billion, up 20.55%, while the annual FY2025 figure was $8.4 billion, N/A changed from the prior year.
  • Net Income for Q1 2026 was $2.9 billion at Gsk, up from $1.3 billion in the prior quarter.
  • Over five years, Net Income peaked at $11.9 billion in Q3 2022 and troughed at $83.2 million in Q3 2024.
  • A 5-year average of $2.7 billion and a median of $2.3 billion in 2023 define the central range for Net Income.
  • Biggest five-year swings in Net Income: crashed 96.33% in 2024 and later soared 3885.36% in 2025.
  • Year by year, Net Income stood at $733.1 million in 2022, then skyrocketed by 559.28% to $4.8 billion in 2023, then fell by 24.31% to $3.7 billion in 2024, then plummeted by 65.45% to $1.3 billion in 2025, then surged by 128.74% to $2.9 billion in 2026.
  • Business Quant data shows Net Income for GSK at $2.9 billion in Q1 2026, $1.3 billion in Q4 2025, and $3.3 billion in Q3 2025.